Welcome to mtm laboratories AG mtm's CINtec® technology, based on the detection of a specific cellular biomarker p16 (p16INK4a with the proprietary E6H4™ clone), offers the potential for highly specific and accurate diagnosis of even symptomless early stage cervical cancer. mtm is currently marketing CINtec® Histology and CINtec® Cytology as adjunctive tools for the early detection of cervical cancer. In addition, mtm is developing a further advanced version to detect p16 the Cervatec® ELISA Assay. Cervidx.com~Site InfoWhoisTrace RouteRBL Check
